Lack of response to octreotide in Cushing's syndrome due to metastatic adrenocortical carcinoma.
Functional metastatic adrenocortical carcinoma is an uncommon cause of Cushing's syndrome, which rarely responds to conventional treatment. A patient presenting with Cushing's syndrome secondary to adrenocortical carcinoma underwent surgical resection. Postoperatively, she developed metastatic disease resistant to conventional chemotherapy. Octreotide, a somatostatin analogue which is effective in the treatment of several types of neuroendocrine tumour, was tried to ameliorate her secretory symptoms, but without any therapeutic effect.
Chan
N N
NN
Department of Endocrinology, Imperial College School of Medicine, Chelsea & Westminster Hospital, London, UK.
Isaacs
A J
AJ
D018268:Adrenocortical Carcinoma / Q000150:complications*; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D015282:Octreotide / Q000627:therapeutic use*; D013004:Somatostatin / Q000031:analogs & derivatives
D000893:Anti-Inflammatory Agents; D006728:Hormones; D013004:Somatostatin; D015282:Octreotide; D006854:Hydrocortisone